×

Princeton University Acquires Protea's LAESI(R) Technology Platform

MORGANTOWN, W.Va., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) ("Protea") announced today that Princeton University has purchased Protea's LAESI DP-1000 Instrument System for direct molecular analysis. The system will be used in Princeton's Frick Chemistry Laboratory for the screening of microbial samples to identify new molecular entities that may hold promise as new antimicrobial therapeutics.

"We are pleased that Princeton's Frick Chemistry Laboratory will be applying our proprietary LAESI technology to the discovery of novel antimicrobials and other therapeutic molecules; this is a field that is today of critical importance to the pharmaceutical industry and to global human health," stated Steve Turner, Protea's CEO.

"Bacteria use a wide range of small molecules to detect and respond to their environment and to communicate, collaborate, or compete with other microbes. The small molecules underlying this complex chemical language, their functions and biosynthetic pathways, comprise the primary focus of our research efforts, and Protea's DP-1000 system is an ideal analytical tool that will benefit various aspects of our work," stated Mohammad Seyedsayamdost, PhD., Associate Professor of Chemistry, Princeton University. He continued, "This group of small molecules has traditionally served as a prolific source of drugs or drug leads, therefore, our studies will also aim to identify therapeutically useful small molecules."

The LAESI DP-1000 Instrument System allows the direct identification of molecules in living cells and microbial samples, with analysis completed in seconds to minutes.

About Protea Biosciences Group, Inc.

Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical, agricultural, and life science industries. Protea has developed a new, fully automated, molecular information technology platform, known as "LAESI" (Laser Ablation Electrospray Ionization), that enables the direct analysis of molecules without the need for sample preparation. Large molecular datasets are generated on native biological samples that can also be visually displayed as 2D and 3D images. Protea maintains its own laboratory facilities where services are provided to its clients, using LAESI and complementary technologies and expertise.

Forward-Looking Statements

This press release may contain certain statements relating to future results, which are forward looking statements. These statements are not historical facts, but instead represent only the company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the company's control. It is possible that the company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the company and its business, including factors that potentially could materially affect the company's financial results, are contained in the company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.

CONTACT: Protea Biosciences Group, Inc., 955 Hartman Run Road, Morgantown, WV 26505 USA Phone: 304.292.2226 Fax: 304.292.7101 haddon.goodman@proteabio.com https://proteabio.com/investors

Source:Protea Biosciences, Inc.